{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:33:37Z","timestamp":1793291617906,"version":"4.5.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010105","name":"Savvaerksejer Jeppe Juhl og Hustru Ovita Juhls Mindelegat","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010105","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sino-Danish Center for Education and Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41391-026-01142-3","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:33:42Z","timestamp":1786041222000},"page":"958-967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From fungus fighter to cancer slayer: itraconazole as a multifaceted candidate for drug-resistant prostate cancer"],"prefix":"10.1038","volume":"29","author":[{"given":"Luciano O.","family":"Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina G.","family":"Papoutsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9944-1214","authenticated-orcid":false,"given":"Jos\u00e9 M. A.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"1142_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/medsci8030028","volume":"8","author":"A Barsouk","year":"2020","unstructured":"Barsouk A, Padala SA, Vakiti A, Mohammed A, Saginala K, Thandra KC, et al. Epidemiology, staging and management of prostate cancer. Med Sci. 2020;8:3.","journal-title":"Med Sci"},{"key":"1142_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1142_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrc801","volume":"2","author":"SR Denmeade","year":"2002","unstructured":"Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2:389\u201396.","journal-title":"Nat Rev Cancer"},{"key":"1142_CR4","first-page":"232","volume":"22","author":"C Huggins","year":"1972","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232\u201340.","journal-title":"CA Cancer J Clin"},{"key":"1142_CR5","first-page":"552","volume":"75","author":"D Chakrabarti","year":"2025","unstructured":"Chakrabarti D, Albertsen P, Adkins A, Kishan A, Murthy V, Parker C, et al. The contemporary management of prostate cancer. CA Cancer J Clin. 2025;75:552\u201386.","journal-title":"CA Cancer J Clin"},{"key":"1142_CR6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238\u201344.","journal-title":"JAMA"},{"key":"1142_CR7","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317:2532\u201342.","journal-title":"JAMA"},{"key":"1142_CR8","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501\u201311.","journal-title":"Oncogene"},{"key":"1142_CR9","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song XL, Li XA, Chen M, Guo J, Yang DH, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;68:100962.","journal-title":"Drug Resist Updat"},{"key":"1142_CR10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","volume":"87","author":"S Gillessen","year":"2025","unstructured":"Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, et al. Management of patients with advanced prostate cancer. Report from the 2024 advanced prostate cancer consensus conference (APCCC). Eur Urol. 2025;87:157\u2013216.","journal-title":"Eur Urol"},{"key":"1142_CR11","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.mayocp.2015.10.010","volume":"90","author":"JC Park","year":"2015","unstructured":"Park JC, Eisenberger MA. Advances in the treatment of metastatic prostate cancer. Mayo Clin Proc. 2015;90:1719\u201333.","journal-title":"Mayo Clin Proc"},{"key":"1142_CR12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/iju.13512","volume":"25","author":"K Komura","year":"2018","unstructured":"Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25:220\u201331.","journal-title":"Int J Urol"},{"key":"1142_CR13","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1142_CR14","doi-asserted-by":"crossref","unstructured":"Lima TS, Iglesias-Gato D, Souza LDO, Stenvang J, Lima DS, Roder MA, et al. Molecular profiling of docetaxel-resistant prostate cancer cells identifies multiple mechanisms of therapeutic resistance. Cancers. 2021;13:1290.","DOI":"10.3390\/cancers13061290"},{"key":"1142_CR15","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","journal-title":"Cell"},{"key":"1142_CR16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.euo.2024.12.014","volume":"8","author":"D Seguier","year":"2025","unstructured":"Seguier D, Parent P, Duterque-Coquillaud M, Labreuche J, Fromont-Hankard G, Dariane C, et al. Emergence of neuroendocrine tumors in patients treated with androgen receptor pathway inhibitors for metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2025;8:581\u201390.","journal-title":"Eur Urol Oncol"},{"key":"1142_CR17","first-page":"9","volume":"8","author":"A Khorasanchi","year":"2025","unstructured":"Khorasanchi A, Hong F, Yang Y, Singer EA, Wang P, Li M, et al. Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches. Cancer Drug Resist. 2025;8:9.","journal-title":"Cancer Drug Resist"},{"key":"1142_CR18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fonc.2013.00313","volume":"3","author":"J Stenvang","year":"2013","unstructured":"Stenvang J, Kumler I, Nygard SB, Smith DH, Nielsen D, Brunner N, et al. Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front Oncol. 2013;3:313.","journal-title":"Front Oncol"},{"key":"1142_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01275-4","volume":"28","author":"R Mohi-Ud-Din","year":"2023","unstructured":"Mohi-Ud-Din R, Chawla A, Sharma P, Mir PA, Potoo FH, Reiner Z, et al. Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects. Eur J Med Res. 2023;28:345.","journal-title":"Eur J Med Res"},{"key":"1142_CR20","first-page":"521","volume":"9","author":"P Pantziarka","year":"2015","unstructured":"Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent. Ecancermedicalscience. 2015;9:521.","journal-title":"Ecancermedicalscience"},{"key":"1142_CR21","doi-asserted-by":"crossref","unstructured":"Zonfa CE, Thyagarajan A, Sahu RP. Repurposing itraconazole in combination with chemotherapy and immune checkpoint inhibitor for cancer. Med Sci. 2026;14:55.","DOI":"10.3390\/medsci14010055"},{"key":"1142_CR22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/CMR.1.2.187","volume":"1","author":"RA Fromtling","year":"1988","unstructured":"Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev. 1988;1:187\u2013217.","journal-title":"Clin Microbiol Rev"},{"key":"1142_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41585-018-0077-y","volume":"15","author":"V Patel","year":"2018","unstructured":"Patel V, Liaw B, Oh W. The role of ketoconazole in current prostate cancer care. Nat Rev Urol. 2018;15:643\u201351.","journal-title":"Nat Rev Urol"},{"key":"1142_CR24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1634\/theoncologist.2012-314","volume":"18","author":"ES Antonarakis","year":"2013","unstructured":"Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, et al. Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist. 2013;18:163\u201373.","journal-title":"Oncologist"},{"key":"1142_CR25","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.clgc.2013.11.015","volume":"12","author":"DL Suzman","year":"2014","unstructured":"Suzman DL, Antonarakis ES. High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer. Clin Genitourin Cancer. 2014;12:e51\u20133.","journal-title":"Clin Genitourin Cancer"},{"key":"1142_CR26","volume":"13","author":"TS Lima","year":"2022","unstructured":"Lima TS, Souza LO, Iglesias-Gato D, Elversang J, Jorgensen FS, Kallunki T, et al. Itraconazole reverts ABCB1-mediated docetaxel resistance in prostate cancer. Front Pharmacol. 2022;13:869461.","journal-title":"Front Pharmacol"},{"key":"1142_CR27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","volume":"17","author":"J Kim","year":"2010","unstructured":"Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17:388\u201399.","journal-title":"Cancer Cell"},{"key":"1142_CR28","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1021\/acs.jmedchem.5b01718","volume":"59","author":"JR Pace","year":"2016","unstructured":"Pace JR, DeBerardinis AM, Sail V, Tacheva-Grigorova SK, Chan KA, Tran R, et al. Repurposing the clinically efficacious antifungal agent itraconazole as an anticancer chemotherapeutic. J Med Chem. 2016;59:3635\u201349.","journal-title":"J Med Chem"},{"key":"1142_CR29","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3892\/ol.2017.6325","volume":"14","author":"H Tsubamoto","year":"2017","unstructured":"Tsubamoto H, Ueda T, Inoue K, Sakata K, Shibahara H, Sonoda T. Repurposing itraconazole as an anticancer agent. Oncol Lett. 2017;14:1240\u20136.","journal-title":"Oncol Lett"},{"key":"1142_CR30","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1248\/bpb.22.1355","volume":"22","author":"K Takara","year":"1999","unstructured":"Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999;22:1355\u20139.","journal-title":"Biol Pharm Bull"},{"key":"1142_CR31","volume":"131","author":"W Wang","year":"2020","unstructured":"Wang W, Dong X, Liu Y, Ni B, Sai N, You L, et al. Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K\/AKT\/mTOR, and ROS pathways. Biomed Pharmacother. 2020;131:110661.","journal-title":"Biomed Pharmacother"},{"key":"1142_CR32","doi-asserted-by":"crossref","unstructured":"Zhang WBA, Ramzan Z, Williams TA, Subramaniyan I, Edpuganti V, Kallem RR, et al. Itraconazole exerts its antitumor effect in esophageal cancer by suppressing the HER2\/AKT signaling pathway. Mol Cancer Ther. 2010;20:1904\u2013.15","DOI":"10.1158\/1535-7163.MCT-20-0638"},{"key":"1142_CR33","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1002\/jcp.26506","volume":"233","author":"S Fattahi","year":"2018","unstructured":"Fattahi S, Pilehchian Langroudi M, Akhavan-Niaki H. Hedgehog signaling pathway: epigenetic regulation and role in disease and cancer development. J Cell Physiol. 2018;233:5726\u201335.","journal-title":"J Cell Physiol"},{"key":"1142_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-3-29","volume":"3","author":"T Sheng","year":"2004","unstructured":"Sheng T, Li C, Zhang X, Chi S, He N, Chen K, et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer. 2004;3:29.","journal-title":"Mol Cancer"},{"key":"1142_CR35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","volume":"18","author":"AM Skoda","year":"2018","unstructured":"Skoda AM, Simovic D, Karin V, Kardum V, Vranic S, Serman L. The role of the Hedgehog signaling pathway in cancer: a comprehensive review. Bosn J Basic Med Sci. 2018;18:8\u201320.","journal-title":"Bosn J Basic Med Sci"},{"key":"1142_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature01493","volume":"422","author":"DN Watkins","year":"2003","unstructured":"Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature. 2003;422:313\u20137.","journal-title":"Nature"},{"key":"1142_CR37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2011.10.015","volume":"76","author":"G Raz","year":"2012","unstructured":"Raz G, Allen KE, Kingsley C, Cherni I, Arora S, Watanabe A, et al. Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer. Lung Cancer. 2012;76:191\u20136.","journal-title":"Lung Cancer"},{"key":"1142_CR38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.devcel.2016.07.026","volume":"38","author":"E Pak","year":"2016","unstructured":"Pak E, Segal RA. Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy. Dev Cell. 2016;38:333\u201344.","journal-title":"Dev Cell"},{"key":"1142_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0509-3","volume":"15","author":"A Hanna","year":"2016","unstructured":"Hanna A, Shevde LA. Hedgehog signaling: modulation of cancer properties and tumor mircroenvironment. Mol Cancer. 2016;15:24.","journal-title":"Mol Cancer"},{"key":"1142_CR40","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrm3598","volume":"14","author":"J Briscoe","year":"2013","unstructured":"Briscoe J, Therond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013;14:416\u201329.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1142_CR41","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1242\/dev.083691","volume":"141","author":"R Petrova","year":"2014","unstructured":"Petrova R, Joyner AL. Roles for Hedgehog signaling in adult organ homeostasis and repair. Development. 2014;141:3445\u201357.","journal-title":"Development"},{"key":"1142_CR42","doi-asserted-by":"crossref","unstructured":"Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW. Targeting the sonic Hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers. 2016;8:22.","DOI":"10.3390\/cancers8020022"},{"key":"1142_CR43","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nature02962","volume":"431","author":"SS Karhadkar","year":"2004","unstructured":"Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004;431:707\u201312.","journal-title":"Nature"},{"key":"1142_CR44","doi-asserted-by":"crossref","first-page":"12561","DOI":"10.1073\/pnas.0404956101","volume":"101","author":"P Sanchez","year":"2004","unstructured":"Sanchez P, Hernandez AM, Stecca B, Kahler AJ, DeGueme AM, Barrett A, et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci USA. 2004;101:12561\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1142_CR45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.14715\/cmb\/2017.63.8.22","volume":"63","author":"H Gao","year":"2017","unstructured":"Gao H, Song Q, Yang J, Yu S, Zhao J, Yu G. Carnosol inhibits Hedgehog signaling pathway in both LNCaP and DU145 prostate cancer cell lines. Cell Mol Biol. 2017;63:104\u20138.","journal-title":"Cell Mol Biol"},{"key":"1142_CR46","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2018.11.015","volume":"1866","author":"MR Makena","year":"2020","unstructured":"Makena MR, Ranjan A, Thirumala V, Reddy AP. Cancer stem cells: road to therapeutic resistance and strategies to overcome resistance. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165339.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1142_CR47","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","volume":"158","author":"N Aceto","year":"2014","unstructured":"Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158:1110\u201322.","journal-title":"Cell"},{"key":"1142_CR48","doi-asserted-by":"crossref","unstructured":"Pietrobono S, Stecca B. Targeting the oncoprotein smoothened by small molecules: focus on novel acylguanidine derivatives as potent smoothened inhibitors. Cells. 2018;7:272.","DOI":"10.3390\/cells7120272"},{"key":"1142_CR49","doi-asserted-by":"crossref","unstructured":"Xie H, Paradise BD, Ma WW, Fernandez-Zapico ME. Recent advances in the clinical targeting of Hedgehog\/GLI signaling in cancer. Cells. 2019;8:394.","DOI":"10.3390\/cells8050394"},{"key":"1142_CR50","doi-asserted-by":"crossref","unstructured":"Nguyen NM, Cho J. Hedgehog pathway inhibitors as targeted cancer therapy and strategies to overcome drug resistance. Int J Mol Sci. 2022;23:1733.","DOI":"10.3390\/ijms23031733"},{"key":"1142_CR51","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/jdv.16230","volume":"34","author":"R Dummer","year":"2020","unstructured":"Dummer R, Ascierto PA, Basset-Seguin N, Dreno B, Garbe C, Gutzmer R, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020;34:1944\u201356.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1142_CR52","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1158\/1078-0432.CCR-07-4282","volume":"14","author":"S Narita","year":"2008","unstructured":"Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, et al. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res. 2008;14:5769\u201377.","journal-title":"Clin Cancer Res"},{"key":"1142_CR53","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.18632\/oncotarget.2932","volume":"6","author":"M Mimeault","year":"2015","unstructured":"Mimeault M, Rachagani S, Muniyan S, Seshacharyulu P, Johansson SL, Datta K, et al. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer. Oncotarget. 2015;6:3887\u2013903.","journal-title":"Oncotarget"},{"key":"1142_CR54","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-11-0923","volume":"71","author":"C Metcalfe","year":"2011","unstructured":"Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against smoothened antagonists. Cancer Res. 2011;71:5057\u201361.","journal-title":"Cancer Res"},{"key":"1142_CR55","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1158\/1535-7163.MCT-15-0729-T","volume":"15","author":"B Chen","year":"2016","unstructured":"Chen B, Trang V, Lee A, Williams NS, Wilson AN, Epstein EH Jr., et al. Posaconazole, a second-generation triazole antifungal drug, inhibits the hedgehog signaling pathway and progression of basal cell carcinoma. Mol Cancer Ther. 2016;15:866\u201376.","journal-title":"Mol Cancer Ther"},{"key":"1142_CR56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.canlet.2015.11.006","volume":"370","author":"J Zhou","year":"2016","unstructured":"Zhou J, Zhu G, Huang J, Li L, Du Y, Gao Y, et al. Non-canonical GLI1\/2 activation by PI3K\/AKT signaling in renal cell carcinoma: a novel potential therapeutic target. Cancer Lett. 2016;370:313\u201323.","journal-title":"Cancer Lett"},{"key":"1142_CR57","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1038\/sj.onc.1208928","volume":"24","author":"D Javelaud","year":"2005","unstructured":"Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene. 2005;24:5742\u201350.","journal-title":"Oncogene"},{"key":"1142_CR58","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1073\/pnas.0700776104","volume":"104","author":"B Stecca","year":"2007","unstructured":"Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK\/AKT pathways. Proc Natl Acad Sci USA. 2007;104:5895\u2013900.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1142_CR59","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.celrep.2015.09.063","volume":"13","author":"B Han","year":"2015","unstructured":"Han B, Qu Y, Jin Y, Yu Y, Deng N, Wawrowsky K, et al. FOXC1 activates smoothened-independent hedgehog signaling in basal-like breast cancer. Cell Rep. 2015;13:1046\u201358.","journal-title":"Cell Rep"},{"key":"1142_CR60","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1038\/s41388-017-0098-7","volume":"37","author":"N Li","year":"2018","unstructured":"Li N, Truong S, Nouri M, Moore J, Al Nakouzi N, Lubik AA, et al. Non-canonical activation of hedgehog in prostate cancer cells mediated by the interaction of transcriptionally active androgen receptor proteins with Gli3. Oncogene. 2018;37:2313\u201325.","journal-title":"Oncogene"},{"key":"1142_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02742-0","volume":"11","author":"H Deng","year":"2020","unstructured":"Deng H, Huang L, Liao Z, Liu M, Li Q, Xu R. Itraconazole inhibits the Hedgehog signaling pathway thereby inducing autophagy-mediated apoptosis of colon cancer cells. Cell Death Dis. 2020;11:539.","journal-title":"Cell Death Dis"},{"key":"1142_CR62","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canlet.2016.10.034","volume":"385","author":"X Wang","year":"2017","unstructured":"Wang X, Wei S, Zhao Y, Shi C, Liu P, Zhang C, et al. Anti-proliferation of breast cancer cells with itraconazole: Hedgehog pathway inhibition induces apoptosis and autophagic cell death. Cancer Lett. 2017;385:128\u201336.","journal-title":"Cancer Lett"},{"key":"1142_CR63","doi-asserted-by":"crossref","first-page":"e15255","DOI":"10.1200\/jco.2015.33.15_suppl.e15255","volume":"33","author":"K Inoue","year":"2015","unstructured":"Inoue K, Tsubamoto H, Sonoda T, Ikuta S, Tani S, Yamanaka N. Efficacy of combination chemotherapy with itraconazole for treating metastatic pancreatic cancer in the second-line setting. J Clin Oncol. 2015;33:e15255\u2013e.","journal-title":"J Clin Oncol"},{"key":"1142_CR64","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.1200\/JCO.2020.38.15_suppl.6049","volume":"38","author":"A Madariaga","year":"2020","unstructured":"Madariaga A, Marastoni S, Colombo I, Mandilaras V, Cabanero M, Bruce J, et al. Phase I\/II trial assessing hydroxychloroquine and itraconazole in women with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-01). J Clin Oncol. 2020;38:6049.","journal-title":"J Clin Oncol"},{"key":"1142_CR65","doi-asserted-by":"crossref","unstructured":"Sumanasuriya S, De Bono J. Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise. Cold Spring Harb Perspect Med. 2018;8:a030635.","DOI":"10.1101\/cshperspect.a030635"},{"key":"1142_CR66","first-page":"E7276","volume":"112","author":"SA Head","year":"2015","unstructured":"Head SA, Shi W, Zhao L, Gorshkov K, Pasunooti K, Chen Y, et al. Antifungal drug itraconazole targets VDAC1 to modulate the AMPK\/mTOR signaling axis in endothelial cells. Proc Natl Acad Sci USA. 2015;112:E7276\u201385.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1142_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13917-5","volume":"11","author":"T Long","year":"2020","unstructured":"Long T, Qi X, Hassan A, Liang Q, De Brabander JK, Li X. Structural basis for itraconazole-mediated NPC1 inhibition. Nat Commun. 2020;11:152.","journal-title":"Nat Commun"},{"key":"1142_CR68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1289\/ehp.5785","volume":"111","author":"JA Zarn","year":"2003","unstructured":"Zarn JA, Bruschweiler BJ, Schlatter JR. Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase. Environ Health Perspect. 2003;111:255\u201361.","journal-title":"Environ Health Perspect"},{"key":"1142_CR69","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5414\/CPP45377","volume":"45","author":"B Schneider","year":"2007","unstructured":"Schneider B, Gerdsen R, Plat J, Dullens S, Bjorkhem I, Diczfalusy U, et al. Effects of high-dose itraconazole treatment on lipoproteins in men. Int J Clin Pharmacol Ther. 2007;45:377\u201384.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1142_CR70","volume":"161","author":"J Qi","year":"2023","unstructured":"Qi J, Cheng W, Gao Z, Chen Y, Shipton ML, Furkert D, et al. Itraconazole inhibits endothelial cell migration by disrupting inositol pyrophosphate-dependent focal adhesion dynamics and cytoskeletal remodeling. Biomed Pharmacother. 2023;161:114449.","journal-title":"Biomed Pharmacother"},{"key":"1142_CR71","volume":"13","author":"C Xu","year":"2022","unstructured":"Xu C, Zhuo Y, Liu Y, Chen H. Itraconazole Inhibits the Growth of Cutaneous Squamous Cell Carcinoma by Targeting HMGCS1\/ACSL4 Axis. Front Pharmacol. 2022;13:828983.","journal-title":"Front Pharmacol"},{"key":"1142_CR72","first-page":"1573","volume":"39","author":"K Chen","year":"2018","unstructured":"Chen K, Cheng L, Qian W, Jiang Z, Sun L, Zhao Y, et al. Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-beta\/SMAD2\/3 signaling. Oncol Rep. 2018;39:1573\u201382.","journal-title":"Oncol Rep"},{"key":"1142_CR73","volume":"9","author":"X Dong","year":"2021","unstructured":"Dong X, Liu Y, Deng X, Shao J, Tian S, Chen S, et al. C1GALT1, Negatively Regulated by miR-181d-5p, Promotes Tumor Progression via Upregulating RAC1 in Lung Adenocarcinoma. Front Cell Dev Biol. 2021;9:707970.","journal-title":"Front Cell Dev Biol"},{"key":"1142_CR74","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1158\/1078-0432.CCR-20-1916","volume":"26","author":"DE Gerber","year":"2020","unstructured":"Gerber DE, Putnam WC, Fattah FJ, Kernstine KH, Brekken RA, Pedrosa I, et al. Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020;26:6017\u201327.","journal-title":"Clin Cancer Res"},{"key":"1142_CR75","volume":"15","author":"X Guan","year":"2025","unstructured":"Guan X, Han L. Itraconazole inhibits the Wnt\/beta-catenin signaling pathway to induce tumor-associated macrophages polarization to enhance the efficacy of immunotherapy in endometrial cancer. Front Oncol. 2025;15:1590095.","journal-title":"Front Oncol"},{"key":"1142_CR76","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.1158\/1538-7445.AM2024-5286","volume":"84","author":"Y Takimoto","year":"2024","unstructured":"Takimoto Y, Tsubamoto H, Sakata K, Isono-Taniguchi R, Ueda T, Shibahara H. Abstract 5286: M2 to M1 repolarization of tumor-associated macrophages via the lysosomal effect of itraconazole. Cancer Research. 2024;84:5286 (6_Supplement).","journal-title":"Cancer Research"},{"key":"1142_CR77","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1038\/s41388-018-0375-0","volume":"37","author":"MC Lin","year":"2018","unstructured":"Lin MC, Chien PH, Wu HY, Chen ST, Juan HF, Lou PJ, et al. C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer. Oncogene. 2018;37:5780\u201393.","journal-title":"Oncogene"},{"key":"1142_CR78","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/1878-0261.13489","volume":"18","author":"MC Lin","year":"2024","unstructured":"Lin MC, Chuang YT, Wu HY, Hsu CL, Lin NY, Huang MC, et al. Targeting tumor O-glycosylation modulates cancer-immune-cell crosstalk and enhances anti-PD-1 immunotherapy in head and neck cancer. Mol Oncol. 2024;18:350\u201368.","journal-title":"Mol Oncol"},{"key":"1142_CR79","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.21037\/tau-20-1205","volume":"10","author":"NM Fonseca","year":"2021","unstructured":"Fonseca NM, Roberts ME, Wyatt AW. A marrow-minded look at immune checkpoint blockade resistance in metastatic castration resistant prostate cancer. Transl Androl Urol. 2021;10:4009\u201313.","journal-title":"Transl Androl Urol"},{"key":"1142_CR80","doi-asserted-by":"crossref","first-page":"e1644109","DOI":"10.1080\/2162402X.2019.1644109","volume":"8","author":"H Taghizadeh","year":"2019","unstructured":"Taghizadeh H, Marhold M, Tomasich E, Udovica S, Merchant A, Krainer M. Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives. Oncoimmunology. 2019;8:e1644109.","journal-title":"Oncoimmunology"},{"key":"1142_CR81","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1002\/jcb.27719","volume":"120","author":"F Jiang","year":"2019","unstructured":"Jiang F, Xing HS, Chen WY, Du J, Ruan YL, Lin AY, et al. Itraconazole inhibits proliferation of pancreatic cancer cells through activation of Bak-1. J Cell Biochem. 2019;120:4333\u201341.","journal-title":"J Cell Biochem"},{"key":"1142_CR82","doi-asserted-by":"crossref","first-page":"13979","DOI":"10.3390\/ijms140713979","volume":"14","author":"A Gonnissen","year":"2013","unstructured":"Gonnissen A, Isebaert S, Haustermans K. Hedgehog signaling in prostate cancer and its therapeutic implication. Int J Mol Sci. 2013;14:13979\u20134007.","journal-title":"Int J Mol Sci"},{"key":"1142_CR83","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10585-008-9176-0","volume":"26","author":"GN Naumov","year":"2009","unstructured":"Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis. 2009;26:51\u201360.","journal-title":"Clin Exp Metastasis"},{"key":"1142_CR84","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","volume":"32","author":"DJ Kim","year":"2014","unstructured":"Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32:745\u201351.","journal-title":"J Clin Oncol"},{"key":"1142_CR85","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01475-0","volume":"38","author":"AW Mohamed","year":"2021","unstructured":"Mohamed AW, Elbassiouny M, Elkhodary DA, Shawki MA, Saad AS. The effect of itraconazole on the clinical outcomes of patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a randomized controlled study. Med Oncol. 2021;38:23.","journal-title":"Med Oncol"},{"key":"1142_CR86","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1021\/mp4003249","volume":"10","author":"N Fotaki","year":"2013","unstructured":"Fotaki N, Klein S. Mechanistic understanding of the effect of PPIs and acidic carbonated beverages on the oral absorption of itraconazole based on absorption modeling with appropriate in vitro data. Mol Pharm. 2013;10:4016\u201323.","journal-title":"Mol Pharm"},{"key":"1142_CR87","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00636-21","volume":"65","author":"KE Stott","year":"2021","unstructured":"Stott KE, Le T, Nguyen T, Whalley S, Unsworth J, Ly VT, et al. Population pharmacokinetics and pharmacodynamics of itraconazole for disseminated infection caused by Talaromyces marneffei. Antimicrob Agents Chemother. 2021;65:e0063621.","journal-title":"Antimicrob Agents Chemother"},{"key":"1142_CR88","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13346-024-01592-z","volume":"15","author":"S Shah","year":"2025","unstructured":"Shah S, Famta P, Sharma A, Kumar R, Pandey G, Vambhurkar G, et al. Quality by design empowered preparation of itraconazole albumin nanoparticles for prostate cancer. Drug Deliv Transl Res. 2025;15:253\u201368.","journal-title":"Drug Deliv Transl Res"},{"key":"1142_CR89","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","volume":"27","author":"N McGranahan","year":"2015","unstructured":"McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27:15\u201326.","journal-title":"Cancer Cell"},{"key":"1142_CR90","doi-asserted-by":"crossref","first-page":"104182","DOI":"10.18632\/oncotarget.22115","volume":"8","author":"AE Ross","year":"2017","unstructured":"Ross AE, Hughes RM, Glavaris S, Ghabili K, He P, Anders NM, et al. Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. Oncotarget. 2017;8:104182\u201392.","journal-title":"Oncotarget"},{"key":"1142_CR91","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/myc.12749","volume":"61","author":"WJ Hoffmann","year":"2018","unstructured":"Hoffmann WJ, McHardy I, Thompson GR. 3rd. Itraconazole induced hypertension and hypokalemia: mechanistic evaluation. Mycoses. 2018;61:337\u20139.","journal-title":"Mycoses"},{"key":"1142_CR92","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1042\/CS20200309","volume":"135","author":"S Kamaraju","year":"2021","unstructured":"Kamaraju S, Mohan M, Zaharova S, Wallace B, McGraw J, Lokken J, et al. Interactions between cardiology and oncology drugs in precision cardio-oncology. Clin Sci. 2021;135:1333\u201351.","journal-title":"Clin Sci"},{"key":"1142_CR93","first-page":"7970","volume":"14","author":"H Yang","year":"2017","unstructured":"Yang H, Hu L, Liu Z, Qin Y, Li R, Zhang G, et al. Inhibition of Gli1-mediated prostate cancer cell proliferation by inhibiting the mTOR\/S6K1 signaling pathway. Oncol Lett. 2017;14:7970\u20136.","journal-title":"Oncol Lett"},{"key":"1142_CR94","volume":"8","author":"S Gupta","year":"2024","unstructured":"Gupta S, To TM, Graf R, Kadel EE 3rd, Reilly N, et al. Real-world overall survival and treatment patterns by PTEN status in metastatic castration-resistant prostate cancer. JCO Precis Oncol. 2024;8:e2300562.","journal-title":"JCO Precis Oncol"},{"key":"1142_CR95","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1021\/acs.jmedchem.8b01252","volume":"61","author":"Y Li","year":"2018","unstructured":"Li Y, Pasunooti KK, Li RJ, Liu W, Head SA, Shi WQ, et al. Novel tetrazole-containing analogues of itraconazole as potent antiangiogenic agents with reduced cytochrome P450 3A4 inhibition. J Med Chem. 2018;61:11158\u201368.","journal-title":"J Med Chem"},{"key":"1142_CR96","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1021\/acsmedchemlett.9b00438","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, Pasunooti KK, Peng H, Li RJ, Shi WQ, Liu W, et al. Design and synthesis of tetrazole- and pyridine-containing itraconazole analogs as potent angiogenesis inhibitors. ACS Med Chem Lett. 2020;11:1111\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"1142_CR97","doi-asserted-by":"crossref","unstructured":"Alhakamy NA, Md S. Repurposing itraconazole loaded PLGA nanoparticles for improved antitumor efficacy in non-small cell lung cancers. Pharmaceutics. 2019;11:685.","DOI":"10.3390\/pharmaceutics11120685"},{"key":"1142_CR98","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3109\/02652048.2015.1065917","volume":"32","author":"HP Thakkar","year":"2015","unstructured":"Thakkar HP, Khunt A, Dhande RD, Patel AA. Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability. J Microencapsul. 2015;32:559\u201369.","journal-title":"J Microencapsul"},{"key":"1142_CR99","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/mc.23565","volume":"62","author":"IM Atawia","year":"2023","unstructured":"Atawia IM, Kushwaha PP, Verma S, Lin S, Shankar E, Abdel-Gawad O, et al. Inhibition of Wnt\/beta-catenin pathway overcomes therapeutic resistance to abiraterone in castration-resistant prostate cancer. Mol Carcinog. 2023;62:1312\u201324.","journal-title":"Mol Carcinog"},{"key":"1142_CR100","first-page":"149","volume":"36","author":"K Inoue","year":"2016","unstructured":"Inoue K, Tsubamoto H, Sakata K, Sakane R, Hao H, Hirota S, et al. Expression of hedgehog signals and growth inhibition by itraconazole in endometrial cancer. Anticancer Res. 2016;36:149\u201353.","journal-title":"Anticancer Res"},{"key":"1142_CR101","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2012.11.017","volume":"23","author":"J Kim","year":"2013","unstructured":"Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23:23\u201334.","journal-title":"Cancer Cell"},{"key":"1142_CR102","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jtcvs.2013.08.035","volume":"147","author":"M You","year":"2014","unstructured":"You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 2014;147:508\u201316.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1142_CR103","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13046-017-0526-0","volume":"36","author":"Q Hu","year":"2017","unstructured":"Hu Q, Hou YC, Huang J, Fang JY, Xiong H. Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells. J Exp Clin Cancer Res. 2017;36:50.","journal-title":"J Exp Clin Cancer Res"},{"key":"1142_CR104","volume":"16","author":"S Jin","year":"2025","unstructured":"Jin S, Liu X, Cai L, Yan J, Li L, Dong H, et al. Itraconazole promotes melanoma cells apoptosis via inhibiting hedgehog signaling pathway-mediated autophagy. Front Pharmacol. 2025;16:1545243.","journal-title":"Front Pharmacol"},{"key":"1142_CR105","doi-asserted-by":"crossref","first-page":"28510","DOI":"10.18632\/oncotarget.15324","volume":"8","author":"G Liang","year":"2017","unstructured":"Liang G, Liu M, Wang Q, Shen Y, Mei H, Li D, et al. Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K\/mTOR signaling pathways. Oncotarget. 2017;8:28510\u201325.","journal-title":"Oncotarget"},{"key":"1142_CR106","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/jps.20963","volume":"96","author":"A Gupta","year":"2007","unstructured":"Gupta A, Unadkat JD, Mao Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci. 2007;96:3226\u201335.","journal-title":"J Pharm Sci"},{"key":"1142_CR107","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1128\/AAC.02931-15","volume":"60","author":"VJ Lempers","year":"2016","unstructured":"Lempers VJ, van den Heuvel JJ, Russel FG, Aarnoutse RE, Burger DM, Bruggemann RJ, et al. Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP. Antimicrob Agents Chemother. 2016;60:3372\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1142_CR108","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1021\/cb600362d","volume":"2","author":"CR Chong","year":"2007","unstructured":"Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ Jr., Liu JO. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol. 2007;2:263\u201370.","journal-title":"ACS Chem Biol"},{"key":"1142_CR109","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.biopha.2011.11.004","volume":"66","author":"R Del Carratore","year":"2012","unstructured":"Del Carratore R, Carpi A, Beffy P, Lubrano V, Giorgetti L, Maserti BE, et al. Itraconazole inhibits HMEC-1 angiogenesis. Biomed Pharmacother. 2012;66:312\u20137.","journal-title":"Biomed Pharmacother"},{"key":"1142_CR110","doi-asserted-by":"crossref","first-page":"44045","DOI":"10.1074\/jbc.M111.278754","volume":"286","author":"BA Nacev","year":"2011","unstructured":"Nacev BA, Grassi P, Dell A, Haslam SM, Liu JO. The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J Biol Chem. 2011;286:44045\u201356.","journal-title":"J Biol Chem"},{"key":"1142_CR111","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jid.2018.12.028","volume":"139","author":"S Chen","year":"2019","unstructured":"Chen S, Zhuang K, Sun K, Yang Q, Ran X, Xu X, et al. Itraconazole Induces Regression of Infantile Hemangioma via Downregulation of the Platelet-Derived Growth Factor-D\/PI3K\/Akt\/mTOR Pathway. J Invest Dermatol. 2019;139:1574\u201382.","journal-title":"J Invest Dermatol"},{"key":"1142_CR112","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/0008-5472.CAN-11-0691","volume":"71","author":"BT Aftab","year":"2011","unstructured":"Aftab BT, Dobromilskaya I, Liu JO, Rudin CM. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res. 2011;71:6764\u201372.","journal-title":"Cancer Res"},{"key":"1142_CR113","volume":"254","author":"L Ban","year":"2020","unstructured":"Ban L, Mei T, Su Q, Li W, Huang Z, Liu L, et al. Anti-fungal drug itraconazole exerts anti-cancer effects in oral squamous cell carcinoma via suppressing Hedgehog pathway. Life Sci. 2020;254:117695.","journal-title":"Life Sci"},{"key":"1142_CR114","first-page":"3160","volume":"96","author":"ZW Zhao","year":"2016","unstructured":"Zhao ZW, Yang LL, Ji JS, Zheng LY, Fang SJ, Wang JL. [Effects and mechanism ofitraconazole on prostate cancer PC-3 cell apoptosis]. Zhonghua Yi Xue Za Zhi. 2016;96:3160\u20133.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1142_CR115","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/auto.28912","volume":"10","author":"R Liu","year":"2014","unstructured":"Liu R, Li J, Zhang T, Zou L, Chen Y, Wang K, et al. Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking. Autophagy. 2014;10:1241\u201355.","journal-title":"Autophagy"},{"key":"1142_CR116","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1073\/pnas.0910872107","volume":"107","author":"J Xu","year":"2010","unstructured":"Xu J, Dang Y, Ren YR, Liu JO. Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci USA. 2010;107:4764\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1142_CR117","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/ijc.29892","volume":"138","author":"N Kangwan","year":"2016","unstructured":"Kangwan N, Kim YJ, Han YM, Jeong M, Park JM, Hahm KB. Concerted actions of ameliorated colitis, aberrant crypt foci inhibition and 15-hydroxyprostaglandin dehydrogenase induction by sonic hedgehog inhibitor led to prevention of colitis-associated cancer. Int J Cancer. 2016;138:1482\u201393.","journal-title":"Int J Cancer"},{"key":"1142_CR118","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.18632\/oncotarget.6765","volume":"7","author":"N Kangwan","year":"2016","unstructured":"Kangwan N, Kim YJ, Han YM, Jeong M, Park JM, Go EJ, et al. Sonic hedgehog inhibitors prevent colitis-associated cancer via orchestrated mechanisms of IL-6\/gp130 inhibition, 15-PGDH induction, Bcl-2 abrogation, and tumorsphere inhibition. Oncotarget. 2016;7:7667\u201382.","journal-title":"Oncotarget"},{"key":"1142_CR119","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2021.39.6_suppl.114","volume":"39","author":"B Lau","year":"2021","unstructured":"Lau B, Crumbaker M, Yam AOW, Marastoni S, Luckhurst M, O\u2019Grady A, et al. A phase I\/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results. Journal of Clinical Oncology. 2021;39:114.","journal-title":"Journal of Clinical Oncology"},{"key":"1142_CR120","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1158\/2767-9764.CRC-22-0037","volume":"2","author":"S Marastoni","year":"2022","unstructured":"Marastoni S, Madariaga A, Pesic A, Nair SN, Li ZJ, Shalev Z, et al. Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer. Cancer Res Commun. 2022;2:293\u2013306.","journal-title":"Cancer Res Commun"},{"key":"1142_CR121","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2018.36.6_suppl.362","volume":"36","author":"M Lee","year":"2018","unstructured":"Lee M, Hong H, Kim W, Friedlander TW, Fong L, Lin AM, et al. A phase II study of itraconazole in biochemically recurrent prostate cancer. Journal of Clinical Oncology. 2018;36:362.","journal-title":"Journal of Clinical Oncology"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01142-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01142-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01142-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:03:27Z","timestamp":1793289807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01142-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":121,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1142"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01142-3","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Generative artificial intelligence (AI) tools (Perplexity AI [accessed 2026; Claude] were used to assist in the preparation of this manuscript for literature searches, language editing, and text drafting; these tools were used under human oversight and do not qualify for authorship. The authors have carefully reviewed, verified, and take full responsibility for all content, including any portions for which the AI tools provided assistance, and affirm that the work complies with relevant journal, institutional, and ethical guidelines on AI use in scholarly publishing.","order":2,"name":"Ethics","label":"<b>Generative AI use<\/b>","group":{"name":"EthicsHeading","label":"Ethics"}}]}}